Oncology · Mantle Cell LymphomaTrial Updateclinicalmid-term

Phase 2 Study of Lisaftoclax and Pirtobrutinib in Relapsed Mantle Cell Lymphoma

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 6:04:15 AM

Assessment confidence: 75% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing phase 2 study of lisaftoclax and pirtobrutinib represents a significant development in the treatment landscape for relapsed mantle cell lymphoma, particularly for patients who have not responded to BTK inhibitors. Success in this trial could reshape treatment guidelines and enhance competitive positioning for companies in the oncology sector. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 25 ranked evidence items (17 high-relevance).

Strategic Assessment

If successful, this combination could offer a new therapeutic option, influencing treatment guidelines and competitive positioning for companies involved in lymphoma therapies. The strongest clinical anchor is Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy (ClinicalTrials.gov), entity match (pirtobrutinib); patient population match (refractory). In Oncology · Mantle Cell Lymphoma, 5 regulatory and 5 competitive items passed relevance filtering for pirtobrutinib.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study. This trial could provide insights into alternative treatment options for patients who have failed existing BTK inhibitors, potentially impacting the market for mantle cell lymphoma therapies.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). Relevant agencies in corpus: FDA, MHRA. Positive trial results may influence future regulatory approvals and label expansions, potentially altering compliance requirements for existing therapies.

Key Risks

Elevated medium regulatory exposure for pirtobrutinib could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma) could weigh on pirtobrutinib through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

If the trial demonstrates efficacy, it could lead to increased market share for the combination therapy, impacting revenue streams for companies involved in lymphoma treatments.
Upside for pirtobrutinib may improve if Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy (ClinicalTrials.gov) delivers favorable follow-through.
Upside for pirtobrutinib may improve if An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Upside for pirtobrutinib may improve if A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor enrollment progress and initial efficacy results from the trial, as well as any safety concerns that may arise.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Drug Trials Snapshots: YARTEMLEA
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
ClinicalTrials.govhigh relevance
Entity match (pirtobrutinib); Patient population match (refractory)
FDA document
View source
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche); Patient population match (refractory)
FDA document
View source
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View source
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View source
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View source
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With Bruton's Tyrosine Kinase Inhibitor and B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View source
Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
BrainChild Bio Initiates CAR T Therapy Study for DIPG Patients
Humanexa Signalsmedium relevance
Moderate corpus alignment

Lactylation and liquid-liquid phase separation related genes influence prognosis and immune characteristics of diffuse large B-cell lymphoma patients.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

pirtobrutinib
mantle cell lymphoma therapies

Commercial impact

medium

If the trial demonstrates efficacy, it could lead to increased market share for the combination therapy, impacting revenue streams for companies involved in lymphoma treatments.

Regulatory impact

medium

Positive trial results may influence future regulatory approvals and label expansions, potentially altering compliance requirements for existing therapies.

What to watch

Monitor enrollment progress and initial efficacy results from the trial, as well as any safety concerns that may arise.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.